Epiq Capital Group, Llc - Net Worth and Insider Trading

Epiq Capital Group, Llc Net Worth

The estimated net worth of Epiq Capital Group, Llc is at least $5 Million dollars as of 2024-05-04. Epiq Capital Group, Llc is the of Quince Therapeutics Inc and owns about 2,860,967 shares of Quince Therapeutics Inc (QNCX) stock worth over $3 Million. Epiq Capital Group, Llc is the of Applied Molecular Transport Inc and owns about 8,337,518 shares of Applied Molecular Transport Inc (AMTI) stock worth over $2 Million. Epiq Capital Group, Llc is also the 10% Owner of Lucira Health Inc and owns about 3,461,764 shares of Lucira Health Inc (LHDXQ) stock worth over $346. Details can be seen in Epiq Capital Group, Llc's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Epiq Capital Group, Llc has not made any transactions after 2022-05-13 and currently still holds the listed stock(s).

Transaction Summary of Epiq Capital Group, Llc

To

Epiq Capital Group, Llc Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Epiq Capital Group, Llc owns 3 companies in total, including Quince Therapeutics Inc (QNCX) , Applied Molecular Transport Inc (AMTI) , and Lucira Health Inc (LHDXQ) .

Click here to see the complete history of Epiq Capital Group, Llc’s form 4 insider trades.

Insider Ownership Summary of Epiq Capital Group, Llc

Ticker Comapny Transaction Date Type of Owner
QNCX Quince Therapeutics Inc 2020-06-12 other: IA/Managing Member 10% owner
AMTI Applied Molecular Transport Inc 2022-05-13 other: Managing member of 10% owner
LHDXQ Lucira Health Inc 2022-12-14 10 percent owner

Epiq Capital Group, Llc Latest Holdings Summary

Epiq Capital Group, Llc currently owns a total of 3 stocks. Among these stocks, Epiq Capital Group, Llc owns 2,860,967 shares of Quince Therapeutics Inc (QNCX) as of June 12, 2020, with a value of $3 Million and a weighting of 56.24%. Epiq Capital Group, Llc owns 8,337,518 shares of Applied Molecular Transport Inc (AMTI) as of May 13, 2022, with a value of $2 Million and a weighting of 43.76%. Epiq Capital Group, Llc also owns 3,461,764 shares of Lucira Health Inc (LHDXQ) as of February 5, 2021, with a value of $346 and a weighting of 0.01%.

Latest Holdings of Epiq Capital Group, Llc

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
QNCX Quince Therapeutics Inc 2020-06-12 2,860,967 0.99 2,818,339
AMTI Applied Molecular Transport Inc 2022-05-13 8,337,518 0.26 2,192,767
LHDXQ Lucira Health Inc 2021-02-05 3,461,764 0.00 346

Holding Weightings of Epiq Capital Group, Llc


Epiq Capital Group, Llc Form 4 Trading Tracker

According to the SEC Form 4 filings, Epiq Capital Group, Llc has made a total of 8 transactions in Quince Therapeutics Inc (QNCX) over the past 5 years, including 8 buys and 0 sells. The most-recent trade in Quince Therapeutics Inc is the acquisition of 9,040 shares on June 12, 2020, which cost Epiq Capital Group, Llc around $400,020.

According to the SEC Form 4 filings, Epiq Capital Group, Llc has made a total of 3 transactions in Applied Molecular Transport Inc (AMTI) over the past 5 years, including 3 buys and 0 sells. The most-recent trade in Applied Molecular Transport Inc is the acquisition of 62,143 shares on May 13, 2022, which cost Epiq Capital Group, Llc around $249,815.

According to the SEC Form 4 filings, Epiq Capital Group, Llc has made a total of 1 transactions in Lucira Health Inc (LHDXQ) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Lucira Health Inc is the acquisition of 3,461,764 shares on February 5, 2021, which cost Epiq Capital Group, Llc around $59 Million.

Insider Trading History of Epiq Capital Group, Llc

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Epiq Capital Group, Llc Trading Performance

GuruFocus tracks the stock performance after each of Epiq Capital Group, Llc's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Epiq Capital Group, Llc is -13.72%. GuruFocus also compares Epiq Capital Group, Llc's trading performance to market benchmark return within the same time period. The performance of stocks bought by Epiq Capital Group, Llc within 3 months outperforms 3 times out of 12 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Epiq Capital Group, Llc's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Epiq Capital Group, Llc

Average Return

Average return per transaction

Outperforming Transactions

8 out of 12 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -7.19
Relative Return to S&P 500(%) -8

Epiq Capital Group, Llc Ownership Network

Ownership Network List of Epiq Capital Group, Llc

No Data

Ownership Network Relation of Epiq Capital Group, Llc


Epiq Capital Group, Llc Owned Company Details

What does Quince Therapeutics Inc do?

Who are the key executives at Quince Therapeutics Inc?

Epiq Capital Group, Llc is the other: IA/Managing Member 10% owner of Quince Therapeutics Inc. Other key executives at Quince Therapeutics Inc include Chief Scientific Officer Guenter Janhofer , President Charles S. Ryan , and director & Chief Executive Officer Dirk Thye .

Quince Therapeutics Inc (QNCX) Insider Trades Summary

Over the past 18 months, Epiq Capital Group, Llc made no insider transaction in Quince Therapeutics Inc (QNCX). Other recent insider transactions involving Quince Therapeutics Inc (QNCX) include a net purchase of 500,436 shares made by David Lamond , a net purchase of 168,000 shares made by Dirk Thye , and a net purchase of 71,762 shares made by Brendan Hannah .

In summary, during the past 3 months, insiders sold 0 shares of Quince Therapeutics Inc (QNCX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 1,871 shares of Quince Therapeutics Inc (QNCX) were sold and 748,198 shares were bought by its insiders, resulting in a net purchase of 746,327 shares.

Quince Therapeutics Inc (QNCX)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Quince Therapeutics Inc Insider Transactions

No Available Data

Epiq Capital Group, Llc Mailing Address

Above is the net worth, insider trading, and ownership report for Epiq Capital Group, Llc. You might contact Epiq Capital Group, Llc via mailing address: One Lombard Street, Suite 200, San Francisco Ca 94111.

Discussions on Epiq Capital Group, Llc

No discussions yet.